Diffuse Systemic Sclerosis

Article1 August 1962Diffuse Systemic SclerosisThe Alfred Stengel Memorial LectureWILLIAM S. MIDDLETON, M.D., M.A.C.P.WILLIAM S. MIDDLETON, M.D., M.A.C.P.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-57-2-183 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Excerpt"There are some who possess that intangible quality known as leadership, to whom all others turn for counsel, guidance, and inspiration. Such was Alfred Stengel, whose sudden and unexpected death on April 10, 1939, deprived American medicine of one of its most distinguished clinicians and robbed the American College of Physicians of a beloved and honored master as well as a loyal and ardent champion" (1).In these terms George Morris Piersol eulogized his late departed friend and long-time associate, whose professional life and activities were so intimately bound to the University of Pennsylvania School of Medicine and the American...References1. PIERSOL GM: Dr. Alfred Stengel. An appreciation. Ann. Intern. Med. 12: 1913, 1939. Google Scholar2. MIDDLETON WS: Some clinical expressions of diffuse collagen disorders. Med. Clin. N. Amer. 37: 1697, 1953. CrossrefGoogle Scholar3. DURAN-REYNALS F: Introduction—conference on the ground substance of the mesenchyme and hyaluronidase. Ann. N. Y. Acad. Sci. 52: 943, 1950. Google Scholar4. CROWLEY N: Hyaluronidase production by hemolytic streptococci of human origin. J. Path. Bact. 56: 27, 1944. CrossrefGoogle Scholar5. QUINN RW: The antihyaluronidase content of human serum. Ann. N. Y. Acad. Sci. 52: 1118, 1950. CrossrefMedlineGoogle Scholar6. KLEMPERERPOLLACKBAEHR PADG: Diffuse collagen disease. J. A. M. A. 119: 331, 1942. CrossrefGoogle Scholar7. NEUMANN E: Die Picrocarminfärbung und ihre Anwendung auf die Entzündungslehre. Arch. Mikrobiol. Anat. 18: 130, 1880. CrossrefGoogle Scholar8. RÖSSLE R: Zum Formenkreis der rheumatischen Gewebsveränderungen, mit besonderer Berücksichtigung der rheumatischen Gefässentzündungen. Arch. Path. Anat. 288: 780, 1933. CrossrefGoogle Scholar9. ALTSCHULEANGEVINE CHDM: Histochemical studies on the pathogenesis of fibrinoid. Amer. J. Path. 25: 1061, 1949. MedlineGoogle Scholar10. MASUGIYÄ-SHU M.: Die diffuse Sklerodermie und ihre Gefässveränderung. Virchow. Arch. Path. Anat. 302: 39, 1938. CrossrefGoogle Scholar11. MULLERBRUNSTINGWINKELMANN SALARK: Calcinosis cutis; its relationship to scleroderma. Arch. Derm. 80: 15, 1959. CrossrefGoogle Scholar12. THIBIERGE G: Contribution a l'ètude des lesions musculaires dans la sclerodermie. Rev. Med. 10: 291, 1890. Google Scholar13. NIXON JA: Sclerodermia and myositis. Lancet 1: 79, 1907. CrossrefGoogle Scholar14. BEERMAN H: The visceral manifestations of scleroderma. Amer. J. Med. Sci. 216: 458, 1948. CrossrefMedlineGoogle Scholar15. ORABONAALBANO MLO: Systemic progressive sclerosis (or visceral scleroderma). Acta Med. Scand. Supp. 333, 1958. Google Scholar16. LINDSAYTEMPLETONROTHMAN JRFES: Lesions of the esophagus in generalized progressive scleroderma. J. A. M. A. 123: 745, 1943. CrossrefGoogle Scholar17. PUGH DG: Roentgenologic manifestations of scleroderma. Amer. J. Med. Sci. 216: 571, 1948. CrossrefMedlineGoogle Scholar18. GETZOWA S: Cystic and compact pulmonary sclerosis in progressive scleroderma. Arch. Path. 40: 99, 1945. Google Scholar19. CHURCHELLIS REAR: Cystic pulmonary fibrosis in generalized scleroderma. Lancet 1: 392, 1950. CrossrefGoogle Scholar20. BALDWINCOURNANDRICHARDS EDADW: Pulmonary insufficiency. II. A study of thirty-nine cases of pulmonary fibrosis. Medicine 28: 1, 1949. CrossrefMedlineGoogle Scholar21. MATSUI S: Über die Pathologie und Pathogenese von Sclerodermie universalis. Mitt. Med. Fahr. (Tokyo) 31: 55, 1924. Google Scholar22. WEISSSTEADWARRENBAILEY SEAJVOT: Scleroderma heart disease. Arch. Intern. Med. 71: 749, 1943. CrossrefGoogle Scholar23. GOETZ RH: The pathology of progressive systemic sclerosis (generalized scleroderma). Clin. Proc. Capetown Postgrad. Med. Ass. 4: 337, 1945. Google Scholar24. GOETZ RH: Heart in generalized scleroderma. Angiology 2: 555, 1951. CrossrefMedlineGoogle Scholar25. MOORESHEEHAN HCHL: The kidney of scleroderma. Lancet 1: 68, 1952. CrossrefMedlineGoogle Scholar26. GLASERSMITH RJDE (editors): Scleroderma with congestive heart failure. Amer. J. Med. 14: 231, 1953. CrossrefMedlineGoogle Scholar27. FISHERRODNAN ERGP: Pathologic observations concerning the kidney in progressive systemic sclerosis. Arch. Path. 65: 29, 1958. MedlineGoogle Scholar28. ROTTENBERGSLOCUMBEDWARDS ENCHJE: Cardiac and renal manifestations in progressive systemic scleroderma. Proc. Mayo Clin. 34: 77, 1959. MedlineGoogle Scholar29. DUDLEYRITCHIESCHILLINGBAKER HRACAWH: Pathologic changes associated with the use of sodium ethylene diamine tetra-acetate in the treatment of hypercalcemia. New Engl. J. Med. 252: 331, 1955. CrossrefMedlineGoogle Scholar30. REUBERBRADLEY MDJE: Acute Versenate nephrosis. J. A. M. A. 174: 263, 1960. CrossrefMedlineGoogle Scholar31. TUFFANELLIWINKELMANN DLRK: Scleroderma and its relationship to the "collagenoses": dermatomyositis, lupus erythematosus, rheumatoid arthritis and Sjögren's syndrome. Amer. J. Med. Sci. 243: 123, 1962. Google Scholar32. WEINBERGERROPESKULKABAUER HWMWJPW: Reiter's syndrome, clinical and pathologic observations. Medicine 41: 35, 1962. CrossrefMedlineGoogle Scholar33. BANKS BM: Is there a common denominator in scleroderma, dermatomyositis, the Libman-Sacks syndrome and polyarteritis nodosa? New Engl. J. Med. 225: 433, 1941. CrossrefGoogle Scholar34. WINKELMANN RK: Treatment of systemic scleroderma. Proc. Mayo Clin. 34: 55, 1959. MedlineGoogle Scholar35. EVANSRUBITSKYPERRY JAHJAW: Treatment of diffuse progressive scleroderma. J. A. M. A. 151: 891, 1953. MedlineGoogle Scholar36. ZARAFONETIS CJ: The treatment of scleroderma: results of potassium para-aminobenzoate therapy in 104 cases, in Inflammation and Diseases of Connective Tissue, ed. by Mills, L. C., and Moyer, J. H., W. B. Saunders Company, Philadelphia, 1961. Google Scholar37. KLEINHARRIS RSB: Treatment of scleroderma, sclerodactylia and calcinosis by chelation (EDTA). Amer. J. Med. 19: 798, 1955. CrossrefMedlineGoogle Scholar38. RUKAVINAMENDELSONPRICEBROWNJOHNSON JGCJMRRSA: Scleroderma (acrosclerosis). I. Treatment of three cases of the non-calcific variety by chelation (EDTA). J. Invest. Derm. 29: 273, 1957. CrossrefMedlineGoogle Scholar39. PRICEBROWNRUKAVINAMENDELSONJOHNSON JMRRJGCSA: Scleroderma (acrosclerosis). II. Tryptophan metabolism before and during treatment by chelation (EDTA). J. Invest. Derm. 29: 289, 1957. CrossrefMedlineGoogle Scholar40. JOHNSON SA: Personal communication. Google Scholar41. ZARAFONETISLORBERHANSON CJSHSM: Association of functioning carcinoid syndrome and scleroderma. Amer. J. Med. Sci. 236: 1, 1958. CrossrefMedlineGoogle Scholar42. SCHERBELSCHMID ALEA: Effect of serotonin inhibitors on connective tissue disease. Cleveland Clin. Quart. 29: 1, 1962. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Washington, D. C.From the Department of Medicine and Surgery, Veterans Administration, Washington, D. C.Presented as the Alfred Stengel Memorial Lecture at the Forty-third Annual Session of The American College of Physicians, Philadelphia, Pennsylvania, April 9-13, 1962.Requests for reprints should be addressed to William S. Middleton, M.D., Department of Medicine and Surgery, Veterans Administration, Washington 25, D. C. Nextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByImpotence in SclerodermaNANCY S. NOWLIN, M.D., JAMES E. BRICK, M.D., DANA J. WEAVER, M.D., DEBORAH A. WILSON, M.D., HOWARD L. JUDD, M.D., JOHN K. H. LU, Ph.D., HAROLD E. CARLSON, M.D.Progressive systemische Sklerodermie (Sklerose)SklerodermieThe arthropathy of relapsing polychondritisRelapsing polychondritis: Review of current status and case reportDe Subitaneis MortibusRelapsing PolychondritisDissecting aneurysms of arteries other than the aortaRelapsing PolychondritisA Syndrome Resembling Relapsing Polychondritis In A Patient With Ulcerative ColitisRelapsing Polychondritis, Rheumatoid Arthritis and BlindnessRetinopathy due to progressive systemic sclerosisAN AUTOPSY CASE OF RELAPSING POLYCHONDRITISRelapsing polychondritisSystemic Scleroderma, Calcinosis Cutis and Parathyroid HyperplasiaRheumatism and Arthritis Review of American and English Literature of Recent Years (Sixteenth Rheumatism Review)CHARLEY J. SMYTH, M.D., F.A.C.P., ROGER L. BLACK, M.D., CHARLES CHRISTIAN, M.D., MACK L. CLAYTON, M.D., F.A.C.S., DONALD F. HILL, M.D., F.A.C.P., JOSEPH LEE HOLLANDER, M.D., F.A.C.P., WILLIAM M. MIKKELSEN, M.D., F.A.C.P., MAX M. MONTGOMERY, M.D., F.A.C.P., CARL M. PEARSON, M.D., F.A.C.P., HUGH A. SMYTHE, M.D., F.R.C.P. (C), L. EMMERSON WARD, M.D., F.A.C.P., HOWARD J. WEINBERGER, M.D., F.A.C.P.Relapsing Polychondritis Clinical and Pathologic Features in Fourteen CasesRONALD L. KAYE, M.D., DONALD A. SONES, M.D. 1 August 1962Volume 57, Issue 2_Part_1Page: 183-197KeywordsHypertensionSclerodermaSurgery Issue Published: 1 August 1962 CopyrightCopyright ©, 1962, by The American College of PhysiciansPDF DownloadLoading ...